As diagnosis, prognosis, and treatment of AML are all strongly guided by its genetic drivers, we analyzed the landscape of PSAT1 expression across different AML mutations and cytogenetic aberrations using RNA-seq from TCGA, BEAT-AML, and Leucegene patient cohorts. The gene discussed is PSAT1; the disease is acute myeloid leukemia.